Mutation or loss of expression of merlin is responsible for neurofibromatosis type 2 (NF2), which is characterized by the development of schwannomas and other tumors of the nervous system. Like the ERM (ezrin-radixin-moesin) proteins, merlin interacts with CD44, a cell-surface receptor for hyaluronan (HA) that promotes tumorigenesis. However, the relationship between merlin and CD44 and the mechanism by which merlin exerts its tumorsuppressor function have not been elucidated. In the present study, we show that increased expression of wildtype merlin in Tr6BC1 schwannoma cells inhibits HA binding to CD44. Furthermore, we demonstrate that the residues required for this inhibitory effect and the interaction between CD44 and merlin lie within the first 50 amino acids of merlin. Overexpression of merlin inhibited subcutaneous growth of Tr6BC1 cells in immunocompromised Rag1 mice. In contrast, knocking down expression of endogenous merlin promoted tumor cell growth, as did overexpression of a merlin deletion mutant (merlinDel-1) that lacks the first 50 amino acids but not of other NH 2 -terminal deletion mutants. Together, our results demonstrate that inhibition of the CD44-HA interaction contributes to the tumor-suppressor function of merlin, and they suggest that merlin inhibits tumor growth, at least in part, by negatively regulating CD44 function.
Introduction
Neurofibromatosis type 2 (NF2) is characterized by the development of schwannomas and other tumors of the nervous system (Evans et al., 1992; Gutmann, 1994; Gutmann et al., 1997) . The product of the NF2 gene is schwannomin/merlin, which shares significant sequence homology with the ezrin-radixin-moesin (ERM) proteins (Rouleau et al., 1993; Trofatter et al., 1993) . Merlin and the ERM proteins are members of the band 4.1 superfamily, all of which contain a FERM (4.1, ezrin, radixin, moesin) domain at their NH 2 -termini. Like the ERM proteins, merlin regulates actin cytoskeletal organization, cell architecture and motility (Algrain et al., 1993; Tsukita et al., 1994) .
CD44, the principal cell-surface receptor for hyaluronan (HA; Stamenkovic et al., 1989; Aruffo et al., 1990) , is one of the transmembrane proteins that interact with ERM proteins and merlin (Tsukita et al., 1994; Hirao et al., 1996; Sainio et al., 1997; Tsukita and Yonemura, 1997; Morrison et al., 2001) . There are numerous isoforms of CD44, the most commonly expressed isoform is the standard form of CD44 (CD44s) that lacks variant exon products. All of the CD44 variants (CD44v) contain insertions of various combinations of variant exons (1-10) located between exons 5 and 16 of the CD44 gene (Screaton et al., 1992 (Screaton et al., , 1993 . In contrast to merlin, which displays tumor-suppressor activity, CD44 promotes tumor invasion and metastasis (Gunthert et al., 1991; Sherman et al., 1994; Lamb et al., 1997; Yu et al., 1997; Stamenkovic, 1999, 2000) .
Merlin has been shown to mediate the contact inhibition of cell growth in vitro via its interaction with CD44 (Morrison et al., 2001 ) and loss of merlin promotes tumorigenesis by destabilizing the cadherin-mediated adherens junctions (Lallemand et al., 2003) . However, neither the mechanism whereby merlin exerts its tumor-suppressing activity nor the precise functional relationship between merlin and CD44 has been fully elucidated. We therefore investigated the possibility that merlin exerts its tumorsuppressing function by negatively regulating CD44 function.
Merlin is composed of an NH 2 -terminal domain (amino acids 1-302), a central a-helical domain (residues 303-478), and a COOH-terminal domain (amino acids 479-595). There are two major merlin isoforms, isoform I and II, which are the products of alternative splicing at near the 3 0 end of NF2 gene Hara et al., 1994) . Only merlin isoform I has been shown to exhibit tumor-suppressing activity (Sherman et al., 1997) . The NH 2 -terminus of merlin shares high sequence homology with the NH 2 -terminal halves of ERM proteins that mediate the binding of these proteins to a variety of molecules in the plasma membrane (Tsukita et al., 1994; Hirao et al., 1996; Yonemura et al., 1998) . Accordingly, merlin mutants that lack part of the NH 2 -terminal ERM-homology domains lose their ability to associate with the plasma membrane (Deguen et al., 1998; Koga et al., 1998) . Genetic analysis of NF2 patients has shown that deletions in the NH 2 -terminal FERM domain occur frequently and are associated with early tumor onset and poor prognosis (Ruttledge et al., 1996) . In the present study, we show that HA binds to Tr6BC1 schwannoma cells and TA3 mammary carcinoma cells in a CD44-dependent manner (Figure 1B-e and f; and C-e and f) and that overexpression of wild-type (wt) merlin in these cells inhibits the binding of HA to CD44 . To identify the domain of merlin that is required for this inhibitory effect, we established five deletion mutants (merlinDel-1-melrinDel-5), each of which bears a nonoverlapping 50-amino acid deletion starting from the NH 2 -termius ( Figure 2a) . wt merlin and each of these deletion mutants were expressed in Tr6BC1 cells and the corresponding transfectants were tested for their HA-binding capacity. Our results show that deletion of the first 50 amino acids (merlinDel-1), but not of the rest of the NH 2 -terminal domain of merlin (merlinDel-2-merlinDel-5), abolishes the observed inhibitory effect of merlin on HA-CD44 binding (Figure 3a ). In addition, the in vitro binding assays revealed that the first 50 amino acids of merlin are required for its ability to bind CD44 ( Figure 5a ). wt merlin displayed a plasma membrane localization, whereas deletion of the first 50 amino acids abolished the membrane localization as indicated by the observation that merlinDel-1 displays diffuse intracellular distribution . We further demonstrated that overexpression of wt merlin inhibited subcutaneous (s.c.) growth of Tr6BC1 in vivo, whereas knocking down endogenous merlin or overexpression of merlinDel-1, but not other four NH 2 -terminal deletion mutants of merlin, promoted Tr6BC1 cell growth in vivo (Figure 8 ). Together, these results suggest that merlin exerts its tumor-suppressor function by negatively regulating the CD44-HA interaction and thereby reducing the protumorigenic activity of CD44.
Results

Increased expression of merlin inhibits the binding of fluorescein-labeled hyaluronan to CD44
The best-characterized intracellular binding partners of CD44 are the ERM proteins and merlin (Tsukita et al., 1994; Hirao et al., 1996; Sainio et al., 1997) . CD44 and ezrin play important roles in promoting tumor metastasis (Yu et al., 1997; Stamenkovic 1999, 2000; Yu et al., 2004; Khanna et al., 2001 Khanna et al., , 2004 , whereas merlin acts as a tumor suppressor (Rouleau et al., 1993; Trofatter et al., 1993; Lutchman and Rouleau, 1995; Sherman et al., 1997; McClatchey et al., 1998; Giovannini et al., 1999 Giovannini et al., , 2000 . Thus far, the functional relationship between CD44 and merlin and the manner in which CD44 affects the tumor-suppressing activity of merlin have not been established. To address these issues, we first assessed the effect of increased expression of merlin (isoform I) on CD44-mediated binding to HA in TA3 mouse mammary carcinoma and Tr6BC1 mouse schwannoma cells.
Western blot analysis of Tr6BC1 and TA3 cell lysates showed that both cell types express endogenously CD44 ( Figure 1A -c, lanes 1 and 5) and merlin ( Figure 1A -a, lanes 1 and 5). Full-length mouse merlin isoform I cDNA was obtained by reverse transcription-polymerase chain reaction (RT-PCR) and cloned into pEF6/v5-His TOPO expression vector, which contains a COOHterminal v5-epitope tag (Invitrogen, Carlsbad, CA, USA). Following sequence verification, the expression construct was stably transfected into Tr6BC1 and TA3 cells. At least three independent colonies from each cell type were identified that expressed a high level of v5-tagged merlin (Tr6BC1 merlin and TA3 merlin , Figure 1A-b ). These cells were tested for their binding to HA, since most of the known functions of CD44 are related to its HA-binding ability, which is tightly regulated (Stamenkovic et al., 1989 , Lesley et al., 1993 Xu and Yu, 2003) .
Tr6BC1 cells predominantly express the standard form of CD44 (CD44s, Figure 1A -c, arrow), whereas TA3 cells express several CD44 variants ( Figure 1A -c, arrowheads) in addition to CD44s ( Figure 1A -c, Yu et al., 1997) . We first verified that binding of HA to these cells was CD44-dependent: as expected, binding of fluorescein-labeled hyaluronan (FL-HA) to Tr6BC1 wt and TA3 wt cells was inhibited by a blocking anti-CD44 antibody KM201 ( Figure 1B -e and C-e) but not by a control anti-ICAM-1 antibody ( Figure 1B -f and C-f). Tr6BC1 and TA3 transfectants containing empty expression vectors (Tr6BC1 wt, TA3 wt ,) or the pooled populations of at least three independent colonies that express a high level of v5-epitope-tagged merlin (Tr6BC1 merlin , TA3 merlin , Figure A -b) were evaluated in the FL-HA-binding assay. The results showed that increased expression of merlin in Tr6BC1 and TA3 cells significantly reduced the CD44-mediated binding to FL-HA ( Figure 1B -b, and -d; and C-b and -d) , without affecting endogenous CD44 expression by these cells (Figure 1 , A-c, B-a, -c, C-a and -c).
The first 50 amino acids of merlin are required for the binding of merlin to CD44 and for inhibition of the CD44-HA interaction Studies have shown that merlin mutants lacking different portions of the NH 2 -terminal ERM-homology domain lose their ability to interact with the plasma membrane (Deguen et al., 1998; Koga et al., 1998) , a finding that is consistent with the possibility that merlin engages CD44 using the segment(s) located in its NH 2 -terminal half. To define the domain of merlin that is required for its inhibitory effect on the CD44-HA interaction, we established five mutants each of which bore a 50-amino acid deletion within the first 250 residues of the NH 2 -terminal portion of merlin. These Merlin inhibits CD44 function Y Bai et al deletions, starting at the NH 2 -terminus, were designated merlinDel-1 to Del-5 ( Figure 2A ). Tr6BC1 cells were stably transfected with cDNAs encoding wt merlin or one of the five deletion mutants of merlin and at least three independent colonies expressing an intermediate to high level of each of these cDNAs were identified ( Figure 2B-a) . The double banding pattern observed by Western blotting analysis is characteristic of merlin and represents phosphorylated and un-phosphorylated forms of the protein (Morrison et al., 2001 ). The slight difference in molecular weight of the merlin deletions reflects the differences in molecular weight of the deleted amino acids. Tr6BC1 transfectants containing the empty expression vector (Tr6BC1 wt ) or wt merlin (Tr6BC1 merlin ), merlinDel-1 (Tr6BC1 merlinDel-1 ), merlinDel-2 (Tr6BC1 merlinDel-2 ), merlinDel-3 (Tr6BC1 merlinDel-3 ), merlinDel-4 (Tr6BC1 merlinDel-4 ) or merlinDel-5 (Tr6BC1 merlinDel-5 ) expressed similar levels of the standard form of CD44 ( Figure 2B-b) . MerlinDel-2, merlinDel-3, merlinDel-4 and merlinDel-5 behaved like wt merlin, inhibiting CD44-mediated FL-HA binding ( Figure 3A , and data not shown). In contrast, deletion of the first 50 amino acids of merlin (merlinDel-1) abrogated the inhibitory effect of the wt molecule on the CD44-HA interaction, suggesting that sequences within this domain mediate the interaction between CD44 and merlin. Consistent with this notion, immunocytochemical analysis revealed that in addition to its intracellular localization, a large fraction of the wt merlin ( Figure 3B -c) and merlinDel-4 (Figure 3 -f) displayed a plasma membrane localization pattern that was similar to that of CD44 ( Figure 3B -a) and a smaller fraction of the merlinDel-2( Figure 3B -e), merlinDel-3 and merlinDel-5 proteins (data not shown) were localized underneath of plasma membrane. In contrast, Construction of Tr6BC1 transfectants expressing wt merlin or merlin deletion mutants #1 to #5 (merlinDel-1 -merlinDel-5). Western blots were performed using anti-v5-antibody (B-a) and anti-CD44 antibody (B-b), and the cell lysates were obtained from theTr6BC1 transfectants expressing v5-epitope-tagged wt merlin (merlin wt , lanes 1-3) and deletion merlin mutants #1 (merlinDel-1, lanes 4-6), #2 (merlinDel-2, lanes 7-9), #3 (melrinDel-3, lanes 10-12), #4 (merlinDel-4, lanes 13-15) and #5 . merlinDel-1 displayed a predominantly diffuse cytosolic localization pattern ( Figure 3B-d) , suggesting that the first 50 amino acids of merlin participate in the recruitment of merlin to the plasma membrane. To obtain quantitative data on the binding affinity between the cell-surface CD44 and HA, we performed an HA-substratum-binding assay using Tr6BC1 wt and Tr6BC1 cells expressing merlin or the merlin deletion mutants; for this purpose, the cells were seeded in triplicate in the HA-bound 96-well plates in the presence of the blocking anti-CD44 antibody, KM201 or a control anti-ICAM-1 antibody. After the unbound cells had been washed away, the HA substratum-bound cells were fixed and stained with crystal violet. The cells were then lysed, and the intensity of the dye was measured in an enzyme-linked immunosorbant assay (ELISA) reader at 540 nm. The results showed that overexpression of merlin, and to a lesser extent overexpression of merlinDel-2-Del-5, reduced the CD44-mediated binding of the cells to HA substratum, but overexpression of merlinDel-1 enhances the binding (Figure 4 ).
To confirm that the first 50 amino acids of merlin are required for binding to the cytoplasmic tail of CD44, we first established a fusion construct between glutathione S-transferase (GST)(pGEX4T1 vector, Amersham Bioscience, Piscataway, NJ, USA) and the cytoplasmic tail of CD44 (GST-CD44 cyto ). The construct was used to transform BL21-DE3 Escherichia coli, and the fusion protein was purified through a GST affinity column (Amersham, Piscataway, NJ, USA). After treatment of the cells with cytochalasin D, v5-tagged wt merlin and the merlin deletion mutants expressed by Tr6BC1 cells ( Figure 2B -a) were extracted with radioimmunoprecipitation assay (RIPA) buffer and bound to the agarose beads conjugated with anti-v5 antibody (Sigma, St Louis, MO, USA). An equal amount of the purified GST-CD44 cyto fusion protein was added to the agarosebound merlin or the merlin deletion mutants. After washing, the bound GST-CD44 cyto was eluted and detected by Western blotting using a polyclonal antibody specifically recognizing the cytoplasmic tail of CD44. The results showed that the first 50 amino acids of merlin are required for CD44 binding to merlin ( Figure 5A ).
Studies have shown that the interaction between the NH 2 -and COOH-terminal halves of merlin maintains merlin in the closed configuration that is required for its tumor-suppressor activity, and that phosphorylation of S518 interferes with the interaction between the NH 2 -and COOH-terminal halves of merlin and inactivates its tumor-suppressor activity (Sherman et al., 1997; Rong et al., 2004; McClatchey and Giovannini, 2005) . To assess how the NH 2 -terminal merlin mutations (Del-1-Del-5) interact with the COOH-terminal half of the molecule, we established a fusion construct between GST (pGEX4T1 vector, Amersham) and the COOHterminal half of merlin (merlin ). This fusion protein was expressed in BL-21 bacteria and purified through a GST affinity column. We then performed a pull-down assay by adding equal amounts of GSTmerlin 303-595 fusion protein to v5 antibody-conjugated agarose beads that were bound to v5 epitope-tagged NH 2 -terminal fragment of wt merlin (merlin 1-302 ), or one of the NH 2 -terminal deletion mutants of merlin (merlin 1-302 Del-1-merlin 1-302 Del-5). After washing, the bound GST-merlin 303-595 was eluted and detected using a polyclonal antibody against a COOH-terminal epitope of merlin ( Figure 5B ). The results showed that as compared to merlin 1-302 , the NH 2 -terminal deletions displayed reduced binding to GST-merlin , and merlin 1-302 Del-1 had the least pronounced effect on the binding ( Figure 5B -b), suggesting that even though merlinDel-1 is incapable of being recruited to the plasma membrane, it is capable of forming inter-and intramolecular head-to-tail associations that most likely underlie its dominant-negative effect on wt merlin.
Expression of merlinDel-1 promotes anchorageindependent growth of Tr6BC1 schwannoma cells Tr6BC1 merlinDel-1 cells displayed an altered morphology with reduced adhesion (Figure 3 and data not shown). The first 50 amino acids of merlin are required for its binding to CD44, and merlin 1-302 Del-1 is capable of binding to the COOH-terminal half of merlin. (A) Binding of GST-CD44 cyto to merlin and the merlin deletion mutants. v5-tagged wt merlin and the merlin deletion mutants expressed by Tr6BC1 cells were extracted with RIPA buffer and bound to the agarose beads conjugated with anti-v5 antibody (Sigma); the agarose beads were then split into two tubes. The bound proteins in one set of the tubes were directly eluted with 2 Â SDS sample buffer and analysed by Western blotting with anti-v5 antibody to detect the bound merlin and merlin deletion mutants (A-a). Equal amounts of the purified GST-CD44 cyto fusion protein were added to the other set of the tubes. After extensive washing, the bound GST-CD44 cyto was eluted and detected by Western blotting using a polyclonal antibody specifically recognizing the cytoplasmic tail of CD44 (A-b). The result showed that the first 50 amino acids of merlin are required for the binding of CD44 to merlin. (B) Interaction between NH 2 -terminal merlin deletion mutants and the COOHterminal half of merlin. v5-tagged merlin 1-302 and merlin 1-302 Del-1-Del-5 expressed by 293 cells were extracted with RIPA buffer and bound to the agarose beads conjugated with anti-v5 antibody (Sigma), and the agarose beads were then split into two tubes. The bound proteins in one set of the tubes were directly eluted with 2 Â SDS sample buffer and analysed by Western blotting using anti-v5 antibody to detect the bound merlin 1-302 (lane 2) and merlin 1-302 Del-1-Del-5 (lane 3-7, B-a). Equal amounts of the purified GSTmerlin 303-595 fusion protein were added to the other set of the tubes. After washing, the bound GST-merlin 303-595 was eluted and detected by Western blotting using a polyclonal antibody against the COOH-terminal half of merlin (B-b). In lane 1 (A and B), only v5-conjugated agarose beads were used.
To determine whether this phenotype reflects an enhanced anchorage-independent growth capacity of the cells, we assessed the ability of Tr6BC1 transfectants to form colonies in soft agar. We found that Tr6BC1 wt cells, which endogenously express merlin, had a limited capacity to form colonies in soft agar and that overexpression of wt merlin, merlinDel-2, merlinDel-3 and merlinDel-4 had a little effect on colony formation, suggesting that endogenous merlin is sufficient to inhibit anchorage-independent growth of Tr6BC1 cells in cell culture. In contrast, overexpression of merlinDel-1 and, to a much lesser extent merlinDel-5, promoted colony formation ( Figure 6 ). The interaction between CD44 and HA has been found to enhance the anchorageindependent growth of breast epithelial cells (ZoltanJones et al., 2003) . It is therefore not surprising that eliminating the inhibitory effect of merlin on the CD44-HA interaction resulted in enhanced anchorage-independent growth of the schwannoma cells.
Expression of merlinDel-1 or knocking down endogenous merlin promotes Tr6BC1 Schwannoma growth in vivo, whereas overexpression of wt merlin inhibits the tumor cell growth To determine whether the effect of merlinDel-1 on anchorage-independent growth of Tr6BC1 cells in vitro reflects its effect on tumorigenesis in vivo, we s.c. injected the pooled populations of Tr6BC1 wt , Tr6BC1 merlinDel-1 , Tr6BC1 merlinDel-3 or Tr6BC1 merlinDel-4 cells into immunocompromised B6.129S7-Rag1 tmMom ( Rag1, Jackson Lab) mice. Once solid tumors became visible, the diameter of each tumor was measured every other day. Tumor volume was then calculated as described (Materials and methods), expressed as the mean7s.d., and used as an indicator of tumor growth rate. Our results showed that expression of merlinDel-1, but not of merlinDel-3 or merlinDel-4, enhanced tumor growth in vivo ( Figure 7A ). To determine the rate of tumor cell proliferation in vivo, 5-bromo-2 0 -deoxy-uridine (BrdU) was injected into mice, and the corresponding tumor sections were stained with anti-BrdU antibody. The results showed that expression of merlinDel-1 but not of merlinDel-3 or merlinDel-4 significantly promoted BrdU incorporation which reflected increased proliferation rate of the tumor cells in vivo ( Figure 7B ).
To further assess whether merlinDel-1 acts in a dominant-negative fashion by interfering with the function of endogenous merlin, we established the retroviral constructs that carry short hairpin RNAs (shRNAs) against merlin or control shRNA ( Figure 8A-a) .
shRNA-mediated RNA interference (RNAi) has been successfully used to deplete or knockdown target gene expression in a variety of systems (Hemann et al., 2003; Hannon and Conklin, 2004; Paddison et al., 2004; Chan et al., 2005) . Tr6BC1 cells were transduced with the retroviruses carrying shRNAs against merlin (shRNA mMerlin1626 and shRNA mMerlin2291 , Figure 8A-a) or the control shRNA (shRNA control , Figure 8A-a) . The pooled populations of puromycin-resistant cells were tested for their expression of merlin, and the results showed that shRNA mMerlin1626 and shRNA mMerlin2291 inhibited more than 70% expression of merlin, whereas shRNA control had no effect ( Figure 8A-b) .
To compare the effects of wt merlin and merlin deletion mutants on s. positioned between cDNAs encoding the puromycinresistance gene and those encoding merlin and the merlin deletion mutants; therefore, all the puromycinresistant cells are expected to express merlin or the merlin mutant. After selection of the infected Tr6BC1 cells, the pooled populations of the drug-resistant cells express a high level of merlin, or one of the merlin deletion mutant proteins ( Figure 8A-c) .
We then used the following infected Tr6BC1 cells in s.c. tumor growth experiments: Tr6BC1 cells expressing wt merlin (Tr6BC1 retro-merlin ) or the merlin deletion mutants (Tr6BC1 retro-merlinDel-1->Del-5 ), or transduced with the retroviruses carrying the empty retroviral expression vector (Tr6BC1 retro-wt ), Tr6BC1 shRNAmMerlin1626 , Tr6BC1 shRNAmMerlin2291 or Tr6BC1 shRNAcontrol . The results showed that overexpression of merlin inhibited the s.c. growth of Tr6BC1 cells; in contrast, overexpression of merlinDel-1 or knocking down merlin with shRNA mMerlin1626 or shRNA mMerlin2291 promoted the tumor cell growth (Figure 8b ). In addition, overexpression of merlinDel-2-Del-5 had little effect on the tumor growth in vivo (Figure 8b ). As the inhibitory effect of merlinDel-2-Del-5 on the CD44-HA binding was much weaker than that of wt merlin (Figure 4) , and the merlinDel-2-Del-5 mutants did not bind well to their COOH-terminal halves (Figure 5b) , it is not surprising that merlinDel-2-Del-5 displayed no significant inhibitory effects on Tr6BC1 growth in vivo. Thus, our results suggest that merlinDel-1 promotes Tr6BC1 growth in a dominant-negative fashion by inhibiting the function of endogenous merlin.
Expression of merlinDel-1 alters the interaction between CD44 and ezrin, and between CD44 and the actin cytoskeleton Increased expression of merlin impairs cell adhesion, spreading and motility, possibly because of its interaction with the actin cytoskeleton (Huynh and Pulst, 1996; Deguen et al., 1998; Pelton et al., 1998; Gutmann et al., 1999b) . As a receptor for a major ECM component, CD44 plays an important role in regulating cell adhesion and migration (Lesley et al., 1993; Sherman et al., 1994; Stamenkovic 2000) . CD44 interacts with both merlin and the ERM proteins (Tsukita et al., 1994; Hirao et al., 1996; Sainio et al., 1997; Tsukita and Yonemura, 1997) . ERM proteins, especially ezrin, are thought to serve as key linkers between CD44 and the actin cytoskeleton. Merlin may compete with ERM proteins for binding to CD44, thereby altering cell adhesion and motility.
wt merlin and merlin deletion mutants expressed in Tr6BC1 cells displayed strong Triton-X-100 insolubility (data not shown), which prevented us from directly assessing the CD44-merlin interaction by immunoprecipitation. However, as is true for CD44, a large fraction of ezrin can be extracted with RIPA buffer (see Materials and methods for details). To determine whether merlin regulates the CD44-HA interaction by affecting the interaction between CD44 and ezrin, and between CD44 and the actin cytoskeleton, we performed immunoprecipitation using anti-CD44 mAb (IM7.8, BD-Pharmingen, San Diego, CA, USA) and cell lysates derived from the various Tr6BC1 transfectants. The precipitated proteins were analysed by Western blotting with anti-ezrin antibody (Sigma). Expression of wt merlin and to a lesser extent expression of merlinDel-2-merlinDel-5 resulted in a reduced association of ezrin with CD44, whereas expression of merlinDel-1 enhanced the association (Figure 9a ). This observation suggests that merlin inhibits the binding of ezrin to CD44 and that a region within the first 50 amino acids of merlin is required for the inhibitory effect.
To determine whether the interaction of CD44 with the actin cytoskeleton is altered in the Tr6BC1 transfectants, the cells were first extracted with CSK buffer, containing 0.5% Triton X-100, and the Triton-X-100-insoluble fractions were extracted with 2 Â sodium dodecyl sulfate (SDS) Laemmli sample buffer. Equal amounts of protein derived from Triton X-100-soluble and -insoluble fractions of the lysates of various Tr6BC1 transfectants were subjected to Western blot analysis using an anti-CD44 antibody (IM7.8) that recognizes all the CD44 isoforms. The results showed that expression of wt merlin and, to a lesser extent, expression of merlinDel-2-merlinDel-5 weakened the association between CD44 and the actin cytoskeleton, whereas expression of merlinDel-1 enhanced the association (Figure 9b ). These observations support the notion that merlin exerts its tumor-suppressor function at least in part by inhibiting interactions between CD44 and ezrin/actin cytoskeleton, thereby inhibiting CD44-HA binding.
Discussion
We have investigated the merlin-dependent regulation of the interaction between CD44 and its ligand, HA and the mechanism whereby the engagement of CD44 by merlin contributes to the tumor-suppressor activity of merlin. We have demonstrated for the first time that increased expression of merlin inhibits the CD44-HA interaction and that the residues required for this inhibitory effect are located within the first 50 amino acids of merlin. Moreover, our pull-down assays using the GST-CD44 cyto fusion protein showed that the first 50 amino acids are required for its ability to bind to CD44. In addition, merlin 1-302 Del-1 bound to GSTmerlin 303-595 with a much higher affinity than did mutant merlin 1-302 Del-2-Del-5. Finally, overexpression of wt merlin inhibited s.c. growth of Tr6BC1 in vivo, whereas knocking down of endogenous merlin or overexpression of merlinDel-1, but not the other NH 2 -terminal deletion mutants of merlin promoted tumor growth. Taken together, these results suggest that inhibition of the CD44-HA interaction by merlin contributes to the tumor-suppressor activity of merlin.
MerlinDel-1 likely promotes s.c. growth of Tr6BC1 in a dominant-negative manner A large number of merlin mutations have been identified in NF2 patients, and a high proportion of these mutations encode NH 2 -or COOH-terminal-truncated merlin proteins, either as a result of premature termination or abnormal splicing out of portions of the NH 2 -terminal domain. These mutants are often associated with a more severe clinical outcome (Merel et al., 1995; Parry et al., 1996; Ruttledge et al., 1996; Deguen et al., 1998; Evans et al., 1998; Koga et al., 1998) . It is widely held that tumor-suppressor mutants often act in a dominant-negative fashion to promote tumorigenesis (Nigro et al., 1989) . Various merlin deletion mutants have been shown to promote tumorigenesis (Koga et al., 1998; Lajeunesse et al., 1998; Giovannini et al., 2000) , but whether their effects are the result of a dominantnegative or a gain-of-function prooncogenic activity has not been resolved. Tr6BC1 cells express merlin endogenously (Figure 1a) , and the results of RT-PCR together with DNA sequencing indicated that both merlin isoforms I and II are expressed (data not shown). There are two possible mechanisms whereby merlinDel-1 could promote the growth of Tr6BC1 cells in vivo. First, merlinDel-1 could act as a dominant-negative regulator by reversing the inhibitory effect of endogenous merlin on the CD44-mediated HA binding, resulting in the abrogation of its tumor-suppressor activity. Alternatively, the COOH-terminal domain of merlin could harbor an intrinsic prooncogenic activity that is masked by the first 50 amino acids. Our observation that (1) overexpression of wt merlin inhibits Tr6BC1 cell growth in vivo, and (2) knocking down of endogenous merlin or overexpressing merlinDel-1 promotes s.c. growth of Tr6BC1 cells suggests that merlinDel-1 acts in a dominant-negative fashion. It has been shown that association of merlin with lipid rafts is critical for its tumor-suppressing activity (Stickney et al., 2004) . Our results indicated that the first 50 amino acids are required for the plasma membrane localization of merlin and that merlin 1-302 Del-1 retains its ability to bind to the COOH-terminal half of merlin. Together, these findings suggest that merlinDel-1 is capable of forming a head-to-tail association with wt merlin, and the complexes that have merlinDel-1 at their N-terminus are retained in the cytoplasm, where they are unable to exert or to effectively exert their tumor-suppressor activity.
Negative regulation of CD44-HA interaction provides a mechanism that underlies the tumor-suppressor function of merlin Like the ERM proteins, merlin binds to several membrane-associated proteins, including CD44 (Tsukita et al., 1994; Sainio et al., 1997) , NHE-RF/EBP50 (Murthy et al., 1998) , and b1-integrin (Obremski et al., 1998) . ERM proteins play important roles in organizing the actincytoskeleton which is essential for cell adhesion and migration. Unlike the ERM proteins, merlin lacks the conventional actin-binding region in its COOH-terminus, but it contains an actin-binding site in its NH 2 -terminal domain and interacts indirectly with the actin cytoskeleton through the actin-binding protein, bII-spectrin (Scoles et al., 1998) . Association of merlin with the actin cytoskeleton is thought to underlie its effects on actin cytoskeletal organization (Gutmann et al., 1999b) , cell spreading (Pelton et al., 1998) and motility (McClatchey et al., 1998) . The ERM proteins and merlin likely play different or even opposite roles in organization of the cortical actin and tumorigenesis by differentially affecting the functions of their common binding partners such as CD44. We have provided data to support this concept in the present study.
It is well established that CD44 plays an important role in promoting tumor growth and metastasis, mainly by mediating tumor cell adhesion to HA (for reviews see Sherman et al., 1994; Stamenkovic, 2000; Martin et al., 2003) . Overproduction of HA promotes anchorageindependent growth of the CD44-expressing breast epithelial cells by inducing an epithelial-mesenchymal transition (Zoltan-Jones et al., 2003) and increasing evidence suggests that ezrin is a key regulator of tumor metastasis Yu et al., 2004) . We show in the present study that increased expression of merlin inhibits the CD44-mediated cell binding to HA and reduces the interaction between CD44 and ezrin, and as well as between CD44 and the actin cytoskeleton. Compared to wt merlin, the merlin deletion mutants (merlinDel-2-Del-5) displayed a reduced ability to inhibit the CD44-HA binding (Figure 4 ) and the interaction between CD44 and ezrin/actin cytoskeleton (Figure 9 ), and they exhibited no significant antischawnnoma effect in vivo. In contrast, the merlin mutant (merlinDel-1) enhanced the interaction between CD44 and HA and between CD44 and ezrin/actin cytoskeleton, and it promotes Tr6BC1 cell growth in vivo. In addition, we have shown that wt merlin 1-302 and merlin Del-1 displayed a much stronger binding affinity to the COOH-terminal half of merlin than do merlin 1-302 Del-2-Del-5. Together, these data suggest that (1) merlin's ability to form a head-to-tail association and to be recruited to the plasma membrane through its interaction with transmembrane proteins, including CD44, is required for its tumor-suppressor activity, and (2) the effects of merlin and ezrin on the CD44-HA interaction contribute to their anti-and protumor activities, respectively.
Crystal structure studies have revealed that the FERM domain of merlin forms a tri-lobed structure that interacts with its COOH-terminal domain (Shimizu et al., 2002) and that the structure of the NH 2 -terminus of merlin is disorganized in solution but likely becomes organized upon interaction with its binding partner (Kang et al., 2002) . In addition, the head-to-tail-bound/ closed form of merlin is required for its tumorsuppressing activity (Sherman et al., 1997; Gutmann et al., 1999a; Rong et al., 2004) . The first 50 amino acids of merlin, which are required for the inhibition of the CD44-HA interaction and of the s.c. growth of Tr6BC1 cells, are located at the NH 2 -terminal extremity. The results of the present study indicate that the first 50 amino acids of merlin are necessary for the recruitment of merlin to the plasma membrane and that merlinDel-1 is capable of forming a head-to-tail association. Thus, merlinDel-1 may disrupt both the head-to-tail intramolecular association and the intermolecular association (oligomerization) seen in wt merlin and also abrogate the interaction that occurs between wt merlin and its downstream binding partner(s)/targets such as Rac and p21-activated kinase (Pak 1, Shaw et al., 2001; Kissil et al., 2003) , which may provide the underlying basis for the tumor-promoting activity of merlinDel-1. Furthermore, CD44-HA binding can induce the formation of large CD44-HA complexes that localize in the lipid rafts (Oliferenko et al., 1999) . The ability of wt merlin to localize and recruit its downstream binding partner(s)/targets, including Rac (Okada et al., 2005) , to specialized plasma membrane domains through its interaction with CD44 is likely to play an important role in the regulation of the physiological functions of this molecule.
Materials and methods
Cells and reagents
Tr6BC1 Schwannoma cells were obtained from European Tissue and Cell Collection. Anti-CD44 (ATCC, BD), -v5 epitope (Invitrogen), -merlin (Santa Cruz, Santa Cruz, CA, USA), -ezrin (Sigma) and -BrdU (Roche, Indianapolis, IN, USA) antibodies were used in the experiments. The polyclonal antibody against the cytoplasmic tail of mouse CD44 (anti-CD44 cyto ) was generated by immunizing rabbits according to Okamoto et al. (2001) .
Reverse transcriptase-polymerase chain reaction (RT-PCR), expression constructions and deletion mutagenesis RT-PCR was performed as described (Yu and Stamenkovic, 2001 ) using total RNAs from mouse Tr6BC1 schwannoma cells and two primer pairs corresponding to 24 nucleotides at the 5 0 and 3 0 extremities of the coding sequences of mouse merlin isoform I or II (under the accession numbers NM_010898 and L27105, respectively). Full-length merlin isoform I was obtained by PCR using mouse brain cDNA as template with Pfu DNA polymerase (Stratagene, La Jolla, CA, USA) and a pair of primers corresponding to 24 nucleotides at the 5 0 and 3 0 ends of the coding sequence of the molecule (NM_010898). The stop codon was omitted from the reverse primer in order to fuse wt merlin to the COOH-terminal v5 epitope tag that is present in the expression vector (pEF6/v5-His TOPO, Invitrogen).
To determine the domain of merlin that engages CD44, five nonoverlapping deletion mutations of merlin (merlinDel-1-merlinDel-5) were established by sequentially deleting 50-amino acid segments of merlin in each mutant starting from the NH 2 -terminus (residues 1-250). The deletion mutagenesis were performed by using full-length merlin isoform I as the template together with the ExSite mutagenesis kit (Stratagene), and five different pairs of appropriate primers corresponding to the sequences of 24 nucleotides before and after the segments intended to be deleted. wt merlin and the merlin deletion mutants, together with their COOH-terminal v5-epitope tags, were released from the pEF6/v5-His-TOPO vector by digestion with PmeI and BamHI and cloned into the retroviral expression vector pQCXIP (BD Bioscience). The retroviruses were generated by using these expression constructs and pVSVG/GP2-293 cells following the manufacturer's instructions (BD Bioscience).
To generate NH 2 -terminal half deletion mutants of merlin, PCR was used to synthesize the NH 2 -terminal fragments of merlinDel-1-merlinDel-5, using a pair of primers corresponding to 24 nucleotides at the 5 0 end of the coding sequence and a stretch of the amino acid residues, 295-302 of merlin (NM_010898). The resulting PCR fragments were cloned into the pEF6/v5-His TOPO vector (Invitrogen) and then subcloned into the retroviral expression vector (pQCXIP, BD Bioscience). The accuracy of all the expression constructs was confirmed by DNA sequencing.
To knock down the expression of merlin in Tr6BC1 cells, two double-stranded oligos against merlin, mMerlin1626 and mMerlin2291 and a control double-stranded oligo ( Figure 8a) were designed using the BLOCK-iTt RNAi Designer Website (Invitrogen). These oligos were cloned into pENTRt/U6 vector (Invitrogen). The U6 promoter, double-stranded oligos and PolIII transcription terminator were excised from pENTRt/U6 vectors and inserted into pQCXIP vectors, so that expression of the corresponding shRNAs was controlled by the U6 promoter, and the expression of puromycin was driven by the CMV promoter.
Stable transfection and retrovirus transduction Lipofectamine (Invitrogen) was used to transfect Tr6BC1 and TA3 cells Stamenkovic, 1999, 2000) with the empty expression vector alone or with the expression constructs containing cDNA inserts that encode wt merlin or various deletion mutants of merlin (merlinDel-1-Del-5, Figure 2A ). The transfected tumor cells were selected for their resistance to blasticidin. The level of expression of the v5-epitope tagged merlin or merlin mutants by independent colonal transfectants was determined by Western blotting with anti-v5 mAb as described (Xu and Yu, 2003) . At least three independent colonies that expressed an intermediate to high level of the transfected genes were identified and used as the pooled populations in the FL-HA-binding assay and in anchorage-independent and s.c. tumor growth experiments.
In addition, Tr6BC1 cells were transduced with the retroviruses carrying the empty retroviral expression vector, wt merlin, one of the merlin deletion mutants or shRNAs against merlin, or the control shRNA according to the manufacturer's instructions. The infected cells were selected for their resistance to puromycin. The expression levels of v5-tagged merlin and the merlin deletion mutants or endogenous merlin were determined by Western blotting with anti-v5 mAb (Invitrogen) or anti-merlin antibody (Santa Cruz), respectively.
FL-HA and HA-substratum-binding assays, and immuocytochemical staining The FL-HA-binding assay was performed as described previously (Xu and Yu, 2003) . Tr6BC1 and TA3 transfectants were cultured in 35-mm dishes for 24 h and 20 mg/ml of FL-HA (CalBiochem, San Diego, CA, USA) was added to the cultured cells in the presence or absence of an anti-CD44 antibody (KM201) or anti-ICAM-1 antibody for an additional 24 h.
To determine the binding affinity between the cell-surface CD44 and the HA substratum, we coated 96-well plates with 500 mg/ml of HA. After washing and blocking these 96-well plates with phosphate-buffered saline solution (PBS) containing 1% bovine serum albumin (BSA), the transfected Tr6BC1 cells were seeded in triplicate onto HA-bound plates in the presence of a blocking anti-CD44 antibody (KM201) or a control anti-ICAM-1 antibody. The unbound cells were washed away, and the HA substratum-bound cells were fixed and stained with crystal violet. The bound cells were then lysed, and the intensity of the dye was measure in an ELISA reader at 540 nm.
For the immunocytochemical staining, Tr6BC1 and TA3 transfectants were cultured in 35-mm dishes for 48 h then fixed with 3.7% paraformaldehyde. The fixed cells were washed with PBS and blocked with 2% BSA. Antibodies against v5-epitope (Invitrogen), merlin (Santa Cruz) and CD44 (IM7.8 mAb, ATCC) were used to detect the appropriate antigens.
Soft agar colony formation assays
For anchorage-independent growth assays, six-well plates were covered with 0.5% agar in Dulbecco's modified Eagle's medium (DMEM) with 10% FBS, and the pooled population of Tr6BC1 transfectants (5 Â 10 3 cells/well) in 0.25% agar was seeded on the top of these six-well plates in triplicate, then incubated in a humidified chamber for 2 weeks. The plates were inspected and 10 randomly selected field were observed and photographed under a 2.5 Â objective and a 10 Â eyepiece. The colonies in the digital photos were counted, and the mean number of colonies/field was calculated and used as the indicator of the growth capacity of the Tr6BC1 transfectants in anchorage-independent manner.
Construction of the GST fusion proteins and pull-down assays
The fusion construct between GST (pGEX4T1 vector, Amersham Bioscience) and the cytoplasmic tail of CD44 (GST-CD44 cyto ) was established and used to transform BL21-DE3 E. coli. The fusion protein was purified through a GST affinity column (Amersham). v5-tagged wt merlin and the merlin deletion mutants expressed by Tr6BC1 cells were extracted using RIPA buffer (50 mM Tris-HCl, pH 7.4, containing 150 mM NaCl, 1 mM MgCl 2 , 1mM CaCl 2 , 1% Triton X-100, 0.1 SDS, 2 mM phenylmethylsulfonyl fluoride phenylmethylsulphonyl fluoride (PMSF), 2 mg/ml leupeptin, 2 mg/ml pepstatin A and 0.5 units/ml aprotinin) and bound to anti-v5 antibody-conjugated agarose beads (Sigma). An equal amount of purified GST-CD44 cyto fusion protein was added to these agarose-bound merlin or the merlin deletion mutants. After washing, the bound GST-CD44 cyto was eluted and detected by Western blotting with the anti-CD44 cyto polyclonal antibody.
To determine the interaction between the NH 2 -terminal merlin deletion mutations (merlin 1-302 Del-1-Del-5) and the COOH-terminal half of merlin, we established a fusion construct between GST (pGEX4T1 vector, Amersham) and the COOH-terminal half of merlin (GST-merlin ). The fusion protein was expressed in BL-21 bacteria and purified through a GST affinity column. Pull-down assays were performed by adding a equal amount of GST-merlin to v5 antibody-conjugated agarose beads that were bound to v5 epitope-tagged merlin 1-302 , or merlin 1-302 Del-1-Del-5. After washing, the bound GST-merlin 303-595 was eluted and detected by a polyclonal antibody against an epitope on the COOH-terminal half of merlin (Santa Cruz).
Protein extraction, immunoprecipitation and Western blot analysis To determine the interaction between CD44 and ezrin in the various Tr6BC1 transfectants, these cells were lysed in RIPA buffer and equal amounts of extracted proteins were used in the immunoprecipitation experiments using anti-CD44 antibody (IM7.8, ATCC) and protein L beads (Pierce, Rockford, IL, USA). Ezrin in the total cell lysates and the immunoprecipitates was detected by Western blotting with anti-ezrin antibody (Sigma).
To determine whether the interaction between CD44 and the actincytoskeleton was altered in these Tr6BC1 transfectants, the transfectants were first extracted with CSK buffer (10 mM PIPES, pH6.8, containing 300 mM sucrose, 150 mM NaCl, 3 mM MgCl2, 1 mM CaCl2 and 1% Triton X-100) for 10 min on ice, then extracted with 2 Â SDS Laemmli sample buffer. Equal amount of proteins derived from Triton X-100-soluble and -insoluble fractions of the various Tr6BC1 transfectants were analysed by Western blotting with an anti-CD44 antibody (mAb IM7.8.1) that recognizes all the CD44 isoforms.
S.c. tumor growth experiments
Pooled populations of Tr6BC1 wt/retro-wt , Tr6BC1 retro-merlin and Tr6BC1merlin Del-1, Del-3, Del-4/retro-merlinDel-1->Del-5 , Tr6BC1 shRNAmMerlin1626 , Tr6BC1 shRNAmMerlin2291 and Tr6BC1 shRNAcontrol were used in s.c. tumor growth experiments, in which 1.5 Â 10 6 Tr6BC1 cells were injected into individual immunocompromised B6.129S7-Rag1 tmMom (Rag1, Jackson Laboratory, Bar Harbor, Maine, USA) mice. Six or eight mice were used for each type of infected Tr6BC1 cell or the Tr6BC1 transfectant. After solid tumors became visible (8-10 days after the injection), the largest and shortest diameters of the solid tumors were measured each 2 or 3 days by a digital caliper for the next 2-5 weeks. The tumor volume was calculated as follows: tumor volume ¼ 1/2 Â (shortest diameter) 2 Â longest diameter (mm 3 ) and used as the indicator of tumor growth rates.
Histology and detection of tumor cell proliferation in vivo
To determine the tumor cell proliferation rate in vivo, 20 mM 5-Bromo-2 0 -deoxy-uridine (BrdU) was injected into each mouse 4 h before killing s.c. solid tumors were removed, fixed, sectioned and stained with H&E as described (Yu and Stamenkovic, 1999) . In addition, the sections were reacted with anti-BrdU antibody to detect proliferating tumor cells in situ.
